ClinicalTrials.gg
CompletedNCT06213805MIMSUpdated Apr 1, 2026

Efficacy and Safety of Minimally Invasive Micro-Sclerostomy (MIMS) in Glaucoma Surgery

An interventional study of Minimally invasive microsclerostomy in Glaucoma, sponsored by Hôpital Privé de la Baie. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Hôpital Privé de la Baie · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Glaucoma with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Glaucoma · France.

Enrollment
30th of 38
23 · median 105
Started
2024
with 2 others
No phase
29 of 54
7 open now
Registered
46th of 54
by date
Lead sponsor
4 of 54
Hôpital Privé de la Baie

Among the 54 studies in Glaucoma with a site in France, this one is the 30th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2024, is one of 29 with no phase, and was the 46th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

10 of the 54 studies in Glaucoma with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Glaucoma with a site in France, or all of them as a file.
02

Study summary

The main objective is to evaluate the effectiveness of MIMS in patients with an indication for glaucoma surgery, compared to traditional surgery. The secondary objective is to assess safety. The investigating ophthalmologist will follow the patients and collect clinical data in order to identify the benefits and complications of MIMS. Patients are expected to experience fewer complications compared to traditional glaucoma surgery.

03

Conditions studied

  • Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years old who agree to participate in the study having signed
  • Primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma with indication for glaucoma surgery (defined as uncontrolled intraocular pressure or worsening of visual fields, despite maximum tolerated medical therapy) and open iridocorneal angle ( trabecular meshwork visible on gonioscopy, Shaffer classification grade 3-4) and healthy and mobile conjunctiva (without scars or adhesions).
  • Chronic angle closure glaucoma with indication for combined glaucoma and cataract surgery

Exclusion criteria

Exclusion Criteria:

  • Presence of other ophthalmological pathologies (except cataract)
  • History of intraocular surgery (unless cataract surgery), history of trauma, or conjunctival scarring in the quadrant planned for surgery
  • Visual acuity lower than "counts fingers" ", closure of the iridocorneal angle (and angle-closure glaucoma unless associated cataract surgery), neovascular glaucoma or neovascularization of the iris, pachymetry \< 490 μm or > 620 μm.
  • Presence of severe systemic pathologies, pregnant or breastfeeding woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Minimally invasive microsclerostomy

    Procedure: Minimally invasive microsclerostomy

Interventions

  • ProcedureMinimally invasive microsclerostomy

    MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure. This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes.

06

What researchers measure

Primary outcomes

  1. Measurement of intraocular pressure by tonometry

    Measure in millimeters of mercury (mmHg)

    Time frame: day 0, day 7, day 14, day 30, month 6, month 9 and month 12 after surgery

Secondary outcomes

  1. visual quality of life VFQ-25,

    25 questions about visual quality of life with Likert scale (1-5 and 1-6)

    Time frame: month 1, month 3, month 12 after surgery

  2. Optical Coherence Tomography

    high-resolution images of the retina and anterior segment

    Time frame: month 3, month 12

  3. Visual field test

    Measure of visual field in degree (°)

    Time frame: month 3, month 12

07

Study locations

3 sites
  • Hôpital Privé de la Baie
    Avranches, 50300, France
  • Clinique Thiers
    Bordeaux, 33100, France
  • Fondation Rothschild
    Paris, 75019, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Mar 2026, 26 months.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's 26 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 19, 2024
StartActual
Jan 15, 2024
Primary completionActual
Mar 26, 2026
CompletionActual
Mar 26, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06213805
Lead sponsor
Hôpital Privé de la Baie
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Jan 15, 2024
Primary completion
Mar 26, 2026
Completion
Mar 26, 2026
Last update
Apr 1, 2026

Study contacts

Ana Miguel, MD
principal investigator · Hôpital Privé de la Baie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion